Lifecore Biomedical, Inc. (FRA:LDE)

Germany flag Germany · Delayed Price · Currency is EUR
6.85
0.00 (0.00%)
At close: Jan 2, 2026
22.32%
Market Cap243.51M
Revenue (ttm)113.70M
Net Income (ttm)-39.14M
Shares Outn/a
EPS (ttm)-1.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open6.85
Previous Close6.85
Day's Range6.85 - 6.85
52-Week Range4.56 - 7.45
Betan/a
RSI48.25
Earnings DateJan 2, 2026

About Lifecore Biomedical

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacture of hyaluronate acid in bulk form; and formulated and filled syringes, cartridges, and vials for injectable products used in treating a range of medical conditions and procedures. It also provides product development services include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot stud... [Read more]

Industry Pharmaceutical Preparations
Founded 1965
Employees 406
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol LDE
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Momentum Builds for Lifecore (LFCR) with New Partnerships and Index Inclusion

Momentum Builds for Lifecore (LFCR) with New Partnerships and Index Inclusion

13 days ago - GuruFocus

HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inves...

18 days ago - PRNewsWire

Lifecore Biomedical to be Added to Nasdaq Biotech Index

CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced...

24 days ago - GlobeNewsWire

Lifecore (LFCR) Secures Key Agreement with Major Pharmaceutical Client

Lifecore (LFCR) Secures Key Agreement with Major Pharmaceutical Client

25 days ago - GuruFocus

Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer

Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product

25 days ago - GlobeNewsWire

Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference

CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced...

26 days ago - Wallstreet:Online

Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference

CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced...

26 days ago - GlobeNewsWire

Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary d...

5 weeks ago - Business Wire

Lifecore Biomedical to Participate in Upcoming Investor Conferences

CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced ...

2 months ago - GlobeNewsWire

Lifecore Biomedical Inc (LFCR) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Lifecore Biomedical Inc (LFCR) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Ongoing Challenges

2 months ago - GuruFocus

Q1 2026 Lifecore Biomedical Inc Earnings Call Transcript

Q1 2026 Lifecore Biomedical Inc Earnings Call Transcript

2 months ago - GuruFocus

Lifecore (LFCR) Reaffirms Financial Outlook for Transition Period through 2025

Lifecore (LFCR) Reaffirms Financial Outlook for Transition Period through 2025

2 months ago - GuruFocus

Lifecore Biomedical Inc (LFCR) Q3 2025 Earnings: EPS Loss of $0. ...

Lifecore Biomedical Inc (LFCR) Q3 2025 Earnings: EPS Loss of $0.29 Beats Estimate, Revenue Surges to $31.1 Million

2 months ago - GuruFocus

Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update

--  Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025 , Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customer...

2 months ago - GlobeNewsWire

Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025

CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced...

2 months ago - GlobeNewsWire

Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company

Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product Represents Second Agreement Signed with Same Major Multinational...

2 months ago - Wallstreet:Online

Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company

Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product

2 months ago - GlobeNewsWire

Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market

CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CD...

2 months ago - GlobeNewsWire

Lifecore Biomedical: Our Fill-Finish CDMO

Laughing Water Capital highlights Lifecore’s growth tailwinds from regulatory shifts and new wins. Learn why short-term noise may be a long-term buying opportunity.

2 months ago - Seeking Alpha

Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events

CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced...

3 months ago - GlobeNewsWire

LIFECORE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating LifeCore Biomedical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In LifeCore (LFCR) To Contact Him Directly To Discuss Their Options If you are a long-term stoc...

3 months ago - GlobeNewsWire

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced...

3 months ago - GlobeNewsWire